- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05501678
Trial of Diphenhydramine for Sleep in Children With Autism
Randomized Placebo-controlled Crossover Trial of Diphenhydramine for Sleep in Children With Autism
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Joe McGrath
- Phone Number: (650)736-1235
- Email: roscoe37@stanford.edu
Study Contact Backup
- Name: Richard Ellks
- Phone Number: (650)736-1235
- Email: ACESleepTrials@stanford.edu
Study Locations
-
-
California
-
Stanford, California, United States, 94305-5719
- Recruiting
- Stanford University
-
Principal Investigator:
- Antonio Y. Hardan, MD
-
Contact:
- Joe McGrath
- Phone Number: 650-736-1235
- Email: roscoe37@stanford.edu
-
Contact:
- Richard Ellks
- Phone Number: (650) 736-1235
- Email: ACESleepTrials@stanford.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria:
Participants will meet the following
- Outpatients between 8 and 17 years of age
- Diagnostic and Statistical Manual, 5th edition (DSM-5) criteria for Autism Spectrum Disorder (ASD) on the basis of clinical evaluation, confirmed with the Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule, 2nd Ed (ADOS-2)
- Males and females
- Availability of polysomnography (PSG) and actigraphy data
- Sleep disturbances as assessed using Children's Sleep Habits Questionnaire (CSHQ) with a score of 41 or higher
- care provider who can reliably bring participant to clinic visits, provide trustworthy ratings, and interacts with participant on a regular basis
- stable medications for at least 4 weeks
- no planned changes in psychosocial and biomedical interventions during the trial
- willingness to provide additional saliva samples and participate in key study procedures (i.e.,safety measurements every visit, PSG at weeks 4 and 8, and wear the actigraphy watch for 2 weeks before the beginning of trial as well as during the 8 weeks of the trial).
Exclusion criteria:
Participants will be excluded if one or more of the following is met
- active suicidal ideation or DSM-5 diagnosis of schizophrenia, schizoaffective disorder, or psychotic disorder
- active medical problems: migraine, asthma, seizure disorder, significant physical illness (e.g., anaphylaxis, serious liver, renal, or cardiac pathology)
- evidence of a genetic mutation known to cause autism or intellectual disability (e.g., Fragile X Syndrome), metabolic, or infectious etiology for the participant's autism on the basis of medical history, neurologic history, and available tests for inborn errors of metabolism and chromosomal analysis
- pregnant or sexually active females not using a reliable method of contraception (urinary tests for pregnancy will be employed in this study)
- individuals taking beta-blockers (local or systemic), benzodiazepines, antiepileptic medications, serotonin selective re-uptake inhibitors, melatonin and antihistamines
- history of hypersensitivity to diphenhydramine
- history of severe side effects from diphenhydramine
- history of adequate trial of diphenhydramine
- current use of any medications known to interact with diphenhydramine such as medications inhibiting CYP2D6
- taking anticholinergic agents (e.g., trihexyphenidyl, thioridazine).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Diphenhydramine, then Placebo
Participants will first receive Diphenhydramine for a 4-week period. A 25 mg dose of Diphenhydramine will be given at bedtime for one week and then will increase to 50 mg if needed and if well tolerated. Participants will then receive Placebo (fake tablet) for a 4-week period. A 25 mg dose of matching Placebo will be given at bedtime for one week and then will increase to 50 mg if needed and if well tolerated. |
25mg (and up to 50mg) Diphenhydramine given orally
Other Names:
Matching Placebo given orally
|
Experimental: Placebo, then Diphenhydramine
Participants will first receive Placebo (fake tablet) for a 4-week period. A 25 mg dose of matching Placebo will be given at bedtime for one week and then will increase to 50 mg if needed and if well tolerated. Participants will then receive Diphenhydramine for a 4-week period. A 25 mg dose of Diphenhydramine will be given at bedtime for one week and then will increase to 50 mg if needed and if well tolerated. |
25mg (and up to 50mg) Diphenhydramine given orally
Other Names:
Matching Placebo given orally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in sleep latency as measured by polysomnography (PSG)
Time Frame: Baseline, Week 4 and Week 8
|
Baseline, Week 4 and Week 8
|
Change from baseline in duration of non-rapid eye movement (NREM) sleep as measured by polysomnography (PSG)
Time Frame: Baseline, Week 4 and Week 8
|
Baseline, Week 4 and Week 8
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in sleep efficiency as measured by polysomnography (PSG) and actigraphy
Time Frame: Baseline, Week 4 and Week 8
|
Baseline, Week 4 and Week 8
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline on Children's Sleep Habits Questionnaire (CSHQ) subscale scores
Time Frame: Baseline, Week 4, Week 8
|
Baseline, Week 4, Week 8
|
Change from baseline on Aberrant Behavior Checklist, Second Edition (ABC-2) subscale scores
Time Frame: Baseline, Week 4, Week 8
|
Baseline, Week 4, Week 8
|
Change from baseline on Parent Sleep Habits Questionnaire Parent (PSHQ) scores
Time Frame: Baseline, Week 4, Week 8
|
Baseline, Week 4, Week 8
|
Change from baseline on Clinical Global Impression Scale (CGI) scores
Time Frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, and Week 8
|
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, and Week 8
|
Change from baseline on Child Behavior Checklist (CBCL) scores
Time Frame: Baseline, Week 4, Week 8
|
Baseline, Week 4, Week 8
|
Change from baseline on Social Responsiveness Scale, Second Edition (SRS-2) scores
Time Frame: Baseline, Week 4, Week 8
|
Baseline, Week 4, Week 8
|
Change from baseline on Repetitive Behavior Scale - Revised (RBS-R) scores
Time Frame: Baseline, Week 4, Week 8
|
Baseline, Week 4, Week 8
|
Change from baseline on Sensory Profile Questionnaire (SPQ) scores
Time Frame: Baseline, Week 4, Week 8
|
Baseline, Week 4, Week 8
|
Change from baseline on Stanford Social Dimension Scale (SSDS) scores
Time Frame: Baseline, Week 4, Week 8
|
Baseline, Week 4, Week 8
|
Change from baseline on Dimensional Assessment of Repetitive Behaviors (DARB) scores
Time Frame: Baseline, Week 4, Week 8
|
Baseline, Week 4, Week 8
|
Change from baseline on NEuroPSYchological Assessment, 2nd Edition (NEPSY-2) Affect Recognition scores
Time Frame: Baseline, Week 4, Week 8
|
Baseline, Week 4, Week 8
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Antonio Y. Hardan, MD, Stanford University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Neurodevelopmental Disorders
- Child Development Disorders, Pervasive
- Autistic Disorder
- Autism Spectrum Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Antiemetics
- Gastrointestinal Agents
- Dermatologic Agents
- Hypnotics and Sedatives
- Anesthetics, Local
- Anti-Allergic Agents
- Sleep Aids, Pharmaceutical
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Antipruritics
- Diphenhydramine
- Promethazine
Other Study ID Numbers
- IRB-66941
- 1P50HD109861 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autism Spectrum Disorder
-
Stanford UniversityCalifornia Department of Developmental ServicesRecruitingAutism Spectrum Disorder | Autistic Disorder | Autism | Autism Spectrum Disorders | Autistic Disorders Spectrum | Autistic Spectrum Disorder | Autistic Spectrum DisordersUnited States
-
Hoffmann-La RocheActive, not recruitingAutism Spectrum Disorder (ASD)United States, Canada, Italy, Spain
-
Axial Therapeutics, Inc.Active, not recruitingAutism Spectrum Disorder (ASD)United States, Australia, New Zealand
-
Technion, Israel Institute of TechnologyCompleted
-
Stanford UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedAutism | Autism Spectrum Disorder (ASD)United States
-
Corporacion Parc TauliUnknown
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyTerminatedAutism Spectrum Disorder (ASD)Spain, United States, Hungary, Poland, Australia, United Kingdom, Brazil, Czechia, France, Italy, Portugal, Slovakia
-
Florida Gulf Coast UniversityCompletedAutism Spectrum Disorder High-FunctioningUnited States
-
Hospital Universitario Dr. Jose E. GonzalezUnknownAutism | Autism SpectrumMexico
-
National Taiwan University HospitalCompletedAutism Spectrum Disorder High-FunctioningTaiwan
Clinical Trials on Diphenhydramine
-
Montefiore Medical CenterCompletedCough Reflex SensitivityUnited States
-
Northwestern UniversityCompletedPain | SurgeryUnited States
-
Qazvin University Of Medical SciencesCompletedAphthous StomatitisIran, Islamic Republic of
-
Jose Lutzky, MDBristol-Myers Squibb; United States Department of DefenseActive, not recruitingMetastatic Uveal MelanomaUnited States
-
Federal State Budgetary Scientific Institution,...Not yet recruiting
-
Albert Schweitzer HospitalMepha Ltd.Completed
-
National Taiwan University HospitalRecruiting
-
Dent Neuroscience Research CenterTerminatedCentral Nervous System Effects of Diphenhydramine | Pharmacokinetics of DiphenhydramineUnited States
-
Procter and GambleCompletedOccasional Sleeplessness